Gemcitabine (Gemzar) / eff Cancer Research Results

GEM, Gemcitabine (Gemzar): Click to Expand ⟱
Features: Chemo
GEM An IV antimetabolic antineoplastic used with cisplatin for inoperable non-small cell lung CA
Treats cancer of pancreas, lung, ovary and breast.

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Inhibition of DNA synthesis (antimetabolite effect) Incorporated into DNA → chain termination Normal dividing cells affected (bone marrow, GI epithelium) P, R, G Direct cytotoxicity Gemcitabine (2′,2′-difluorodeoxycytidine, dFdC) is phosphorylated to the triphosphate form (dFdCTP) which competes with dCTP, gets incorporated into DNA, and blocks DNA chain elongation.
2 Ribonucleotide reductase (RNR) inhibition dFdCDP inhibits RNR → deoxynucleotide pool depletion ↔ (normal proliferating cells also impacted) R, G Nucleotide pool imbalance Gemcitabine diphosphate (dFdCDP) inhibits RNR, reducing available dNTPs and enhancing the chain-termination effect.
3 Apoptosis induction (DNA damage response) DNA damage signaling → caspase activation Toxicity in dividing normal tissues G Execution of cell death Prolonged DNA synthesis arrest and replication stress triggers apoptosis pathways via ATR/Chk1, p53, and caspase cascades.
4 Cell-cycle arrest (S-phase accumulation) S-phase arrest steers cells into apoptosis ↔ G Cytostasis → death Accumulation of stalled replication forks enforces S-phase arrest and amplifies cytotoxicity.
5 DNA damage response signaling (ATR/Chk1/Chk2) Checkpoint activation ↔ R, G Damage signaling Replication stress activates ATR/Chk1/Chk2 and modulates cell-cycle checkpoints and repair responses.
6 NF-κB pro-survival signaling (resistance axis) NF-κB activation can reduce sensitivity ↔ R, G Resistance/modulation In some tumor models, NF-κB and other pro-survival axes mediate resistance to gemcitabine cytotoxicity; inhibition sensitizes cells.
7 Autophagy modulation (response to stress) Autophagy ↑ in some contexts (cytoprotective) ↔ G Adaptive stress response Gemcitabine can induce autophagy as a survival mechanism in some models; autophagy inhibition can sensitize cells in combination studies.
8 Reactive oxygen species (ROS) elevation (indirect) ROS ↑ (reported in some models) ↔ G Stress amplification Some preclinical studies report ROS increases secondary to replication stress; not a primary mechanism but modulates cell-death pathways.
9 Clinical resistance mechanisms (CDA, nucleoside transporters) CDA ↑; hENT1 ↓ correlates with resistance — G Resistance / exposure constraint Cytidine deaminase (CDA) inactivates gemcitabine; lower hENT1 transport reduces uptake — major clinical resistance factors.
10 Bioavailability / pharmacokinetics (IV dosing; systemic exposure) IV infusion achieves systemic levels ↔ — PK constraint Gemcitabine is given systemically (often IV) and achieves cytotoxic blood levels; rapid deamination by CDA and short half-life shape dosing.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (rapid biochemical activation / early metabolic engagement)
  • R: 30 min–3 hr (acute nucleotide pool effects / checkpoint signaling)
  • G: >3 hr (DNA damage response, cell death, phenotype outcomes)
eff, efficacy: Click to Expand ⟱
Source:
Type:
Power to enhance an anti cancer effect
Scientific Papers found: Click to Expand⟱
1158- And,  GEM,    Andrographolide causes apoptosis via inactivation of STAT3 and Akt and potentiates antitumor activity of gemcitabine in pancreatic cancer
TumCP↓, TumCCA↑, Apoptosis↑, STAT3↓, Akt↓, P21↑, BAX↑, cycD1/CCND1↓, cycE/CCNE↓, survivin↓, XIAP↓, Bcl-2↓, eff↑,
6073- CHL,  GEM,    Chlorophyllin exerts synergistic anti-tumor effect with gemcitabine in pancreatic cancer by inducing cuproptosis
- in-vitro, PC, NA
ChemoSen↑, eff↑, AntiTum↑, TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, GSH↓, ROS↑, HSP70/HSPA5↑,
5390- GoldNP,  GEM,  AsP,    Optimizing Gold Nanoparticles for Combination Therapy: Development of Hydrophobic Nanomedical Devices with Gemcitabine and Ascorbyl Palmitate
- in-vitro, BC, 4T1
EPR↑, eff↑,
2387- MET,  GEM,    Metformin Increases the Response of Cholangiocarcinoma Cells to Gemcitabine by Suppressing Pyruvate Kinase M2 to Activate Mitochondrial Apoptosis
- in-vitro, CCA, HCC9810
eff↑, tumCV↓, TumCMig↓, TumCI↓, Apoptosis↑, PKM2↓, PDHB↓,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

GSH↓, 1,   ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

PDHB↓, 1,   PKM2↓, 1,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 3,   BAX↑, 1,   Bcl-2↓, 1,   survivin↓, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 1,  

Protein Folding & ER Stress ⓘ

HSP70/HSPA5↑, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,   cycE/CCNE↓, 1,   P21↑, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

STAT3↓, 1,  

Migration ⓘ

TumCI↓, 2,   TumCMig↓, 2,   TumCP↓, 2,  

Angiogenesis & Vasculature ⓘ

EPR↑, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   eff↑, 4,  

Functional Outcomes ⓘ

AntiTum↑, 1,  
Total Targets: 24

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: eff, efficacy
4 Gemcitabine (Gemzar)
1 Andrographis
1 Chlorophyllin
1 Gold NanoParticles
1 Ascorbyl Palmitate
1 Metformin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:84  Target#:961  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page